Transient Responses to NOTCH and TLX1/HOX11 Inhibition in T-Cell Acute Lymphoblastic Leukemia/Lymphoma by Rakowski, Lesley A. et al.
Transient Responses to NOTCH and TLX1/HOX11
Inhibition in T-Cell Acute Lymphoblastic Leukemia/
Lymphoma
Lesley A. Rakowski
1,2., Erica A. Lehotzky
1,2., Mark Y. Chiang
1,2*
1Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, 2University of Michigan
Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America
Abstract
To improve the treatment strategies of T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), further efforts are needed to
identify therapeutic targets. Dysregulated expression of HOX-type transcription factors occurs in 30–40% of cases of T-ALL.
TLX1/HOX11 is the prototypical HOX-type transcription factor. TLX1 may be an attractive therapeutic target because mice
that are deficient in TLX1 are healthy. To test this possibility, we developed a conditional doxycycline-regulated mouse
model of TLX1-initiated T-ALL. TLX1 induced T-ALL after ,5–7 months with penetrance of 15–60%. Similar to human TLX1-
type T-ALLs, the TLX1-induced tumors were arrested at the cortical stage of T-cell development and acquired activating
NOTCH1 mutations. Inhibition of NOTCH signaling abrogated growth of cell lines derived from the TLX1-induced tumors.
NOTCH inhibition also transiently delayed leukemia progression in vivo. Suppression of TLX1 expression slowed the growth
of TLX1 tumor cell lines. Suppression of TLX1 in vivo also transiently delayed leukemia progression. We have shown that
TLX1 functions as a T-cell oncogene that is active during both the induction and the maintenance phases of leukemia.
However, the effect of suppressing NOTCH or TLX1 was transient. The tumors eventually ‘‘escaped’’ from inhibition. These
data imply that the biological pathways and gene sets impacted by TLX1 and NOTCH have largely lost their importance in
the fully established tumor. They have been supplanted by stronger oncogenic pathways. Although TLX1 or NOTCH
inhibitors may not be effective as single agents, they may still contribute to combination therapy for TLX1-driven acute
leukemia.
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Introduction
Using standard chemotherapy in adults, 5-year survival rates
remain stagnant at 30–40%. Although children with ALL fare
better, more children die from ALL each year than any other
cancer. Relapsed ALL carries a dismal prognosis and is in fact the
fourth most common pediatric malignancy. Furthermore, current
treatments cause serious adverse consequences in as many as one-
third of patients. There is a clear need to identify the key
molecular defects underlying ALL in hopes of generating new
targeted therapies.
Roughly 15% of pediatric and 25% of adult ALL cases are T-
cell ALL (T-ALL). T-ALL cases can be segregated into subclasses
based on the expression of certain, subclass-defining oncogenes
[1]. These oncogenes include HOX transcription factors (e.g.
TLX1/HOX11), beta-helix-loop-helix transcription factors (e.g.
TAL1 and LYL1), LIM-only domain transcriptional co-activators
(e.g. LMO1 and LMO2), MLL fusion genes, and the CALM-AF10
fusion gene. The HOX subclass represents ,30–40% of pediatric
and adult T-ALL cases [1]. Like other subclasses of T-ALL,
HOX-type T-ALLs are associated with activating NOTCH1
mutations and CDKN2A loss of function [1,2]. However, unlike
other subclasses, HOX-type T-ALL is prominently associated with
NUP214-ABL amplifications [3,4], C-MYB tandem duplications
[4], PHF6 mutations [5], PTPN2 deletions [6], and WT1
mutations [7]. These characteristic genetic lesions are acquired
during leukemic progression and uniquely distinguish HOX-type
T-ALLs from other T-ALL classes. However, the role of these
genetic lesions in oncogenesis and leukemia growth is not well
understood.
The prototypical member of the HOX family of transcription
factors is TLX1/HOX11 (hereafter referred to as TLX1). TLX1
belongs to the NKL subfamily of HOX genes that regulates cell
fate and differentiation during normal physiological development
of the spleen and nervous system. TLX1-null mice lack spleens but
are otherwise healthy [8]. TLX1 shares an evolutionarily
conserved DNA-binding homeodomain with other family mem-
bers [9]. A number of TLX1 target genes have been identified.
However, the mechanism by which TLX1-regulated target genes
orchestrate the physiological function of TLX1 is unclear. TLX1 is
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16761not normally expressed in the T-cell lineage. However, genetic
lesions such as chromosomal translocations lead to inappropriate
expression of intact TLX1 proteins. For example, the
t(10;14)(q24;q11) and t(7;10)(q35;q24) translocations in T-ALL
juxtapose the TLX1 gene on chromosome 10 to T cell regulatory
elements (either TCRd in the t(10;14) or the TCRb enhancer in
the t(7;10) [10]. TLX1-positive T-ALL cases have relatively good
prognosis in children [11,12].
TLX1-positive T-ALLs frequently contain activating NOTCH1
mutations [2]. NOTCH1 belongs to a unique family of type I
transmembrane receptors that regulate cell fate decisions and
differentiation during normal physiological development of many
tissues. Normally, NOTCH receptors reside at the cell membrane
in an inactive state (for review see Kopan [13]). NOTCH is kept
inactive by the negative regulatory region (NRR), which includes
the heterodimerization domain (HD). When a NOTCH ligand
binds a NOTCH receptor, a series of proteolytic cleavages occurs
that leads to the release from the plasma membrane and nuclear
translocation of intracellular NOTCH1 (ICN1). Release from the
plasma membrane requires cleavage by c-secretase. c-secretase
inhibitors (GSI) are compounds that inhibit this step and block
NOTCH signaling. Within the nucleus, ICN1 binds the
transcription factor CSL and a member of the Mastermind-like
family to activate transcription [10]. The half-life of ICN1 is very
short as it is quickly targeted for proteosomal degradation by
multiple ‘‘degron’’ signals in its C-terminal PEST domain
[14,15,16,17].
In T-ALL, NOTCH mutations are frequent, occurring in about
55–60% of pediatric and adult T-ALL samples [2,18]. NOTCH
mutations commonly occur in the HD and PEST domains [2].
HD domain mutations destabilize the NRR and trigger ligand-
independent activation [19]. PEST domain mutations remove C-
terminal degron sequences, which improve ICN stability
[14,15,16,17]. Activation of NOTCH in T-ALL drives aberrant
supraphysiological expression of NOTCH target genes. Many of
these targets have been implicated in oncogenesis, such as HES1
and C-MYC [20,21,22,23,24]. Targeting NOTCH signaling in
mouse and cell line models of T-ALL using GSI inhibits leukemia
growth through cell cycle arrest and/or apoptosis [2,25]. These
promising studies have led to early phase clinical trials.
Although dysregulated expression of TLX1 was discovered in
human T-ALL samples [10,26,27], it has been difficult to
recapitulate TLX1-positive T-ALL in murine models. The
leukemogenic potential of TLX1 was first tested in a bone marrow
transplantation experiment model in which murine hematopoietic
stem and progenitor cells (HSPCs) were retrovirally transduced
with TLX1 and then transferred into lethally irradiated recipients
[28]. Two transplanted mice out of twelve mice developed T-ALL.
Transgenic mice that expressed TLX1 under the control of the Em
enhancer developed B-cell lymphomas instead of T-ALL [29].
Others using the retroviral approach failed to generate HOX-
subtype T-ALL [30]. The limited success in these models may be
related to impaired T-lineage reconstitution by HOX-expressing
HSPCs [30].
To bypass the potential negative consequences of expressing
TLX1 in HSPCs, we developed a conditional doxycycline-
inducible mouse model of dysregulated TLX1. In this model,
expression of TLX1 was placed under the control of the Lck-
promoter in order to limit conditional expression to T-lineage
cells. We isolated multiple strains that developed T-ALL with
variable penetrance. The mouse tumors contained activating
NOTCH mutations at high frequency. The tumors exhibited
dependence on persistent NOTCH and TLX1 signaling; however,
neither was absolutely essential for tumor growth. These new
models clearly establish the oncogenic potential of TLX1.
Although inhibiting NOTCH or TLX1 is not sufficient, we have
provided new in vivo models to test therapeutics that target
oncogenic pathways in TLX1-type T-ALL.
Results
T-lineage specific expression of TLX1 can initiate T-ALL
To determine whether TLX1 can initiate T-ALL, we generated
a doxycycline-repressible transgenic mouse system that over-
expresses TLX1 in the T-cell lineage. In this system there are two
transgenes ‘‘L’’ and ‘‘H’’ (Fig. 1A). The ‘‘L’’ transgene expresses
the tetracycline transactivator (TTA) from the proximal Lck
promoter [31]. This promoter drives expression of TTA in early
thymocytes. The ‘‘H’’ transgene expresses the full-length human
TLX1 cDNA under the control of the tet operon. When the two
transgenes are combined, TLX1 is expressed in early thymocytes
and can by repressed by the addition of the drug doxycycline
(Fig. 1B). Founder #24 expresses approximately 2–3-fold higher
levels of TLX1 than Founder #38 as measured by densitometry.
We have completed analysis of two founder lines after a.400
day observation period. In LH mice derived from Founder #24,
lethal T-ALL develops after a median 210 days with a penetrance
of 60% (Fig. 2A). In LH mice derived from Founder #38, lethal
T-ALL develops after a median of 150 days with a penetrance of
15%. Importantly, T-ALL develops only when the L and H
transgenes are combined. The T-ALL is transmissible to
secondary recipients after bone marrow transplantation (Fig. 2B).
The tumors infiltrate the BM, spleen, lymph nodes, thymus, and
blood (Fig. 2C, Fig. S1). The tumors co-express CD4 and CD8
and are thus arrested at the same stage of differentiation as human
TLX1-positive T-ALL [1]. Thymic and lymph node architecture is
completely effaced (Fig. S2). The T-ALLs are FSC
hi, co-express
Thy-1
hi and HSA
hi, and express TLX1 (Fig. 2D and data not
shown). The characteristics of the T-ALLs derived from both
founders appeared similar. Founder #24 had a higher penetrance
presumably because of the higher level of TLX1 expression. For
this reason, we chose Founder #24 for further study. Our data
show that TLX1 is a ‘‘driver’’ oncogenic lesion in T-ALL.
TLX1 T-ALLs spontaneously develop NOTCH activation
Arguably, to be a useful resource to study human disease, a
mouse model should ideally activate pathways that are also
activated in the same disease setting in humans. For this reason,
we screened TLX1 tumors for activation of the NOTCH1
signaling pathway. In T-ALL, activating NOTCH1 mutations
have been detected in 55–60% of human samples including HOX
T-ALL samples [2]. As an initial approach to determine if
NOTCH1 is activated in our T-ALL tumors, we performed a
Western blot with the V1744 antibody. This unique antibody
specifically recognizes the cleaved, activated form of NOTCH1
(ICN1). NOTCH1 was activated in seven out of seven TLX1 T-
ALL tumors (Fig. 3A and data not shown). We also developed a
cell line (9490) derived from one of these tumors. This cell line is
arrested at the CD4
+CD8
+ stage of development (data not shown)
and expresses ICN1 (Fig. 3B). As a comparison, ALL-SIL is a
human-derived TLX1-positive T-ALL that also expresses ICN1
[2]. Since the bands were of varying sizes, we suspected that
truncating mutations occurred in the PEST domain in exon 34.
To test this possibility, we sequenced exon 34 (Table 1). We also
looked for HD mutations in exons 26 and 27. In two-thirds of
cases NOTCH1 was activated by mutations that resemble HD
and PEST mutations found in human T-ALL samples. This
discovery underscores the relevance of this mouse model to
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activation.
NOTCH inhibition blocks T-ALL cell line growth
To determine whether the TLX1 tumors were NOTCH-
dependent, we treated 9490 cells with GSI (JC-19), which blocks
NOTCH cleavage at the plasma membrane. We treated 9490 cells
with GSI for 12 days. As a comparison, we also treated ALL-SIL
cells. In both cell lines, GSI inhibited cell growth (Fig. 3C, D). GSI
induced a 2–3-fold increase in Annexin-5
+/7-AAD
2 apoptotic
cells (Fig. 3E, F). In contrast, GSI did not have any effect on the
cell cycle (data not shown). To verify the effect of GSI in inhibiting
NOTCH activity, we measured levels of NOTCH1 target genes
Dtx1, Hes1, Nrarp, Cd25, and c-Myc after treatment with GSI using
qPCR (Fig. 3G). GSI inhibited expression of these NOTCH1
targets. In light of recent findings that IL-7Ra is a direct target of
NOTCH1 in human T-ALL [32], we also measured IL-7Ra
expression by flow cytometry. GSI did not inhibit IL-7Ra levels
(Fig. S3). Nevertheless, these data suggest that the Notch signaling
pathway is activated, commonly by spontaneous mutation, during
TLX1-induced leukemogenesis. This spontaneous event promotes
leukemia survival.
Inhibition of NOTCH activation transiently delays
leukemia progression in vivo
Because NOTCH withdrawal profoundly inhibited 9490 cell
growth in vitro, we sought to confirm our findings in vivo. In prior
work in a mouse model of TAL1-induced T-ALL, GSI extended
median survival by 15 days [25]. To test whether leukemia growth
depends on NOTCH in our TLX1 T-ALL model, we injected
TLX1 T-ALLs into lethally irradiated syngeneic recipient mice
with rescue bone marrow cells. Control mice received rescue bone
marrow cells only. Three weeks after transplant, we treated half of
the mice with carrier (DMSO) and the other half with GSI.
During each 1-week cycle we treated the mice daily for three days
followed by a four-day recovery period as previously described
[25]. This dosing regimen reduces the gastrointestinal toxicity of
GSI. After a single cycle there was a significant 89% reduction in
percentage of CD4
+CD8
+ T-ALL blasts in the blood of GSI-
treated mice in contrast to placebo-treated mice (Fig. 4A, B).
Furthermore, the median survival of the mice was significantly
longer (by 17 days) in GSI-treated mice than placebo-treated mice
(Fig. 4C). However, the inhibitory effect of GSI was only transient.
The leukemia eventually ‘‘escaped’’ inhibition. To verify that GSI
inhibited NOTCH activity in vivo, we performed a V1744-
Western blot of lymphomas of recipient mice (Fig. 4D). As
expected, GSI-treated mice did not activate NOTCH. These data
confirm that TLX1 T-ALLs require NOTCH activation for
optimal growth in vivo.
Suppression of TLX1 inhibits T-ALL cell line growth
An advantage of our conditional mouse model is that it allowed
us to investigate whether persistant TLX1 expression is required
for tumor maintenance. To address this question, we treated
cultured 9490 cells with doxycycline for 12 days (Fig. 5A).
Doxycycline inhibited growth by 28%, which was statistically
significant (p=0.0439). To verify repression of TLX1 expression,
we showed that TLX1 protein was not detectable after treatment
with doxycycline (Fig. 5B). We also wanted to verify repression of
TLX1 transcriptional activity. Several TLX1 target genes have
been described (e.g. RUNX1, ALDH1A, HMGA2, CCR7, and
SLC2A3) [33,34,35]. Of these only CCR7 has been validated as a
TLX1 target gene in T-ALL. We measured these targets in 9490
cells after doxycyline treatment (Fig. 5C). The expression of
TLX1, CCR7 and SLC2A3 were reduced in the presence of
doxycycline. CCR7 is a chemokine receptor important for T-cell
Figure 1. Conditional transgenic mouse strains with doxycycline-regulated thymic TLX1 expression. (A) Nomenclature and schematic
description of the transgenes used in the study. The L transgene is the tetracycline transactivator (TTA) regulated by the proximal Lck promoter. The
H transgene is the human TLX1 cDNA regulated by the tet-operon. L mice have the L transgene. H mice have the H transgene. Bitransgenic LH mice
have both the L and H transgenes. (B) Western blots showing thymic TLX1 expression in LH thymi derived from two founder lines (Founder #24 on
the left and Founder #38 on the right) using the 1D7 antibody. Dox = Doxycycline. b-actin expression is shown as the loading control.
doi:10.1371/journal.pone.0016761.g001
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as GLUT3) is a glucose transporter protein that may be important
for cellular metabolism in some cancers. In order to verify that the
repression of CCR7 and SLC2A3 were not influenced by
nonspecific effects of doxycycline, we measured these targets in
9490 cells retrovirally transduced to express TLX1. The
Figure 2. TLX1 initiates T-cell acute lymphoblastic leukemia (T-ALL) in a mouse model. (A) Kaplan-Meier curves showing the development
of T-ALL over time in LH mice derived from two founder lines (Founder #24 on the left and Founder #38 on the right). (B) Kaplan-Meier curve
showing that intravenous transfer of 1 million T-ALL cells from LH mice induces T-ALL in lethally irradiated secondary recipient mice. Experiments
were performed for both founder lines at least twice. (C) Flow cytometric analysis of CD4/CD8 expression of T-ALL cells in the bone marrow (BM),
spleen, thymus, lymph nodes (LN) and blood of three representative LH mice. (D) Flow cytometric analysis of CD24/FSC expression of T-ALL cells in
the thymus in three representative LH mice. Mice developing T-ALL were moribund with infiltration with CD4
+CD8
+ CD24
hi cells in hematopoietic
organs.
doi:10.1371/journal.pone.0016761.g002
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16761Figure 3. Murine TLX1 T-ALLs spontaneously activate NOTCH1. (A) Western blot showing activated NOTCH1 expression in thymic
lymphomas of three TLX1 T-ALL mice using the V1744 antibody that detects cleaved NOTCH1. Wildtype (FvB/N) murine thymus is the negative
control. b-actin expression is the loading control. T-ALL #3 has both two subpopulations; one expresses full length activated NOTCH while the other
expresses activated NOTCH1 with truncation (D2351). (B) Western blot showing activated NOTCH1 expression in the 9490 cell line, which is derived
from an LH mouse, and the ALL-SIL cell line, which is derived from a human TLX1 T-ALL patient. b-actin expression is the loading control. (C) 9490
cells and (D) ALL-SIL cells were treated with DMSO (open diamonds) or the NOTCH inhibitor GSI (solid squares) for 12 days. Average cell numbers of
biological triplicates are shown as a function of time. 9490 cells were treated with DMSO control or GSI for 48 hours and stained with Annexin-5 (y-
axis) and 7-AAD (x-axis). Representative dot plots (E) and column graph (F) are shown. Average percent Annexin-5
+/7-AAD
2 cells of biological
triplicates are shown in the column graph. (G) 9490 cells were treated with or without GSI for 24 hours and then assayed for expression of indicated
NOTCH targets by qPCR. Average expression values of experimental triplicates are shown relative to 18s and normalized to DMSO-treated 9490 cells.
These experiments were repeated twice with similar results.
doi:10.1371/journal.pone.0016761.g003
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cell virus derived LTR repeats. Thus, expression of TLX1 is
resistant to doxycycline. Indeed, retrovirally expressed TLX1
‘‘rescued’’ the repression of CCR7 and SLC2A3 in the presence of
doxycycline (Fig. 5D). In addition, ChIP-on-ChIP analysis of ALL-
SIL cells by De Keersmaecker et al. [36] showed that the
promoters of both CCR7 and SLC2A3 were bound by TLX1 with
p-value cutoffs of 5.82E-12 and 5.19E-6 respectively. These data
show that Ccr7 and Slc2a3 are bona-fide target genes of TLX1 in
our T-ALL model.
Because suppression of TLX1 inhibited cell line growth in vitro,
we sought to verify these results in an in vivo system. We injected
9490 cells into lethally irradiated mice with rescue bone marrow
cells. Inhibition of TLX1 with doxycycline reduced the lethality of
the T-ALL from ,90% to ,40% (Fig. 5E). This result was
statistically significant (p=0.0108). To rule out the possibility that
nonspecific effects of doxycycline inhibit leukemia growth, we
tested the effects of doxycycline on 9490 cells that retrovirally
expressed TLX1. Retrovirally expressed TLX1 restored the
lethality of 9490 cells to ,80% in the presence of doxycycline.
This result was of borderline statistical signifiance (p=0.0638). We
also measured lymph node and spleen weights at 4 weeks after
transplant. Doxycycline reduced the cervical lymph node weights
by ,51%, which was statistically significant (Fig. 5F). Doxycycline
had no effect on spleen weights (Fig. 5G). Retrovirally expressed
TLX1 fully restored lymph node weights. These data show that
suppression of TLX1 expression through TLX1-specific effects of
doxycycline inhibits leukemia growth, particularly in lymph nodes.
Suppression of TLX1 transiently delays leukemia
progression in vivo
Our experiments with 9490 cells suggested that TLX1
inhibition can reduce leukemia growth. We next sought to verify
these findings using primary T-ALL cells. We injected primary
TLX1 T-ALL cells into lethally irradiated syngeneic recipient
mice. We treated half of the mice with placebo and the other half
with doxycycline. Control mice received bone marrow cells only.
At 4 weeks after transplant, there was a statistically significant 66%
reduction in percentage of CD4
+CD8
+ T-ALL blasts in the blood
of doxycycline-treated mice in contrast to placebo-treated mice
(Fig. 6A, B). At 3 weeks after transplant, we measured the weights
of the cervical lymph nodes and spleen (Fig. 6C, D). Similar to our
findings with 9490 cells, doxycycline reduced the weight of lymph
nodes by 59%, which was of borderline statistical significance
(p=0.0554). Doxycycline had no effect on spleen weights. The
overall median survival of the mice was longer (by ,13 days) in
doxycycline-treated mice than placebo-treated mice (Fig. 6E). This
result was statistically significant (p=0.0457). However, similar to
the effects of NOTCH inhibition, the effects of TLX1 inhibition
were transient. The tumors eventually ‘‘escaped’’ inhibition. To
verify that doxycycline was inhibiting TLX1 expression and
activity, we measured TLX1 and CCR7 levels by QPCR in the
lymphomas of recipient mice (Fig. 6F). As expected, doxycycline
inhibited expression of TLX1 by ,9 fold and the TLX1 target
CCR7 by ,2.5 fold. Overall, our experiments using 9490 cells
and primary T-ALL cells show that TLX1 suppression inhibits
leukemia growth both in vitro and in vivo. Together, our data
show that TLX1 functions to both initiate and maintain T-ALL.
Concurrent targeting of the NOTCH and TLX1 pathways
inhibits cell cycle progression
Our findings that inhibition of the NOTCH and TLX1
pathways separately had modest effects on leukemia cell growth
led us to consider inhibiting these pathways concurrently.
NOTCH and TLX1 may synergistically cooperate to regulate
shared downstream target genes [37]. Therefore, we reasoned that
inhibiting both pathways simultaneously may have a cooperative
effect. Simultaneous NOTCH and TLX1 inhibition increased
apoptosis by ,45% over NOTCH inhibition alone (Fig. S4). This
difference trended toward but did not achieve statistical signifi-
cance (p=0.07). NOTCH or TLX1 inhibition did not induce cell
cycle arrest (Fig. S5). However, when combined, NOTCH and
TLX1 inhibition significantly inhibited the G1-S transition
(p,0.002). We conclude from these experiments that concurrent
blockade of the NOTCH and TLX1 pathways may inhibit
leukemia cell growth cooperatively.
Discussion
A handful of transcription factors with mutually exclusive
expression patterns define the unique characteristics of the various
subclasses of T-ALL [1]. The HOX family of transcription factors
defines a subclass in which T-cell development is arrested at the
early cortical double-positive stage of T-cell development [1]. An
inducible mouse model of HOX T-ALL would facilitate efforts to
determine the role of HOX proteins in leukemogenesis and
growth of an established leukemia. TLX1 is the prototypical
member of the HOX group. Therefore, we chose to develop a
mouse model in which TLX1 is inappropriately expressed in
immature thymocytes using the doxycycline-regulated transgenic
system. These mice develop T-ALL at low to intermediate levels of
penetrance. The level of penetrance appears to be dose-
dependent. Similar to human TLX1-positive T-ALL, the T-ALL
cells in our mouse model are arrested at the double-positive stage
Table 1. Frequency of activating NOTCH1 mutations in TLX1-initiated T-ALL primary murine tumors.
Mouse ID Exon 26
* Exon 27
* Exon 34
* Consequence
{ Mutation class
1 Sub C @4793 none Ins GT @ 7344 H1598P, D2448 HD + PEST
2 none none none n/a n/a
3 none none Ins C @ 7053 D2351 PEST
4 none Sub C @5003 Ins T @ 7047 L1668P, D2349 HD + PEST
5 none none none n/a n/a
6 none Sub A @5009 Sub T @7138 I1670N, D2380 HD + PEST
Sub, base substitution; Ins, base insertion; HD, heterodimerization domain; n/a, not applicable.
*Numbers correspond to nucleotide positions in Notch1 cDNA;
{numbers indicate amino acid residues in Notch1 at which mutations occur.
doi:10.1371/journal.pone.0016761.t001
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16761Figure 4. TLX1 T-ALLs are sensitive to NOTCH inhibition in vivo. 1 million TLX1 T-ALL cells from LH mice were injected into lethally irradiated
FvB recipients together with rescue syngeneic bone marrow cells. Starting at 3 weeks after transplant, mice were treated with DMSO (Placebo) or GSI
for a total of 3 cycles. During each cycle, DMSO or GSI was injected daily for three days followed by 4 days of rest. Control mice were injected with
rescue syngeneic bone marrow cells alone. At 4 weeks after transplant, the percent circulating CD4
+CD8
+ (DP) cells was measured. Representative dot
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tion factors that are capable of initiating leukemogenesis in mouse
models.
Spontaneous activation of NOTCH1 occurs at high frequency
in many T-ALL mouse models (e.g. TAL1/SCL, OLIG2, and
LMO1/2 transgenic mice; for review see Aster [38]). We have
shown that our TLX1 transgenic mice frequently activate
NOTCH1 via mutations that resemble those found in human
T-ALL. Thus, our TLX1 mouse model joins other T-ALL mouse
models in which activating NOTCH mutations occur spontane-
ously. In these mouse models, no causal connection has been made
between the genetic background of the mice and NOTCH
activation. Activated NOTCH appears to be a separate target.
Our data raises the possibility that NOTCH inhibitors may
effectively treat patients with TLX1-positive T-ALL. Here we have
shown that NOTCH inhibition with the drug GSI induces
apoptosis and delays leukemia progression by ,17 days in vivo.
However, eventually the mice succumb to T-ALL despite
NOTCH inhibition. Our results are similar to a previous study
by Kelliher and coworkers [25] using TAL1 transgenic mice,
which acquire NOTCH1 mutations at high frequency. In these
mice, GSI prolonged survival by ,15 days. In both studies, the
tumors eventually escape NOTCH inhibition. In summary,
inhibiting NOTCH has only a modest effect on leukemia growth.
The reason for tumor recurrence in both studies is unclear. We
have shown that GSI effectively silences NOTCH activation in
tumors. Therefore, the mechanism of resistance does not appear to
be failure of GSI to inactivate NOTCH signaling. It is possible
that the NOTCH-inactive T-ALL cells that ‘‘escape’’ GSI may
have switched to an alternative pathway that phenocopies
NOTCH signaling. For example, prolonged treatment of Ph
+
CML and ALL cells with imatinib frequently leads to a switch
from dependence on ABL signaling to dependence on src family
kinases [39]. Ectopic over-expression of some NOTCH targets
(e.g. C-MYC, LEF-1 and IL-7RA) can partly or fully substitute for
NOTCH signaling to drive leukemia growth despite blockade of
Notch signaling [32,40,41]. It is possible that the tumor cells have
found alternative mechanisms to activate expression of these
NOTCH targets in the absence of NOTCH signaling. A second
possibility is that NOTCH inactivation is compensated by
mechanisms regulated by the microenvironment. In our study
and in the Kelliher group’s study, GSI treatment inhibited T-ALL
cells in culture to a far greater degree than T-ALL cells in vivo. It
is possible that the tumor microenvironment induces pathways in
T-ALL cells that partly compensate for loss of NOTCH signaling.
Indeed, induction of c-Myc may be the only effector of NOTCH
signaling that cannot be duplicated through compensatory
mechanisms [42]. These data suggest that NOTCH inhibitors
may contribute to T-ALL therapy, but will likely need to be
combined with other agents such as mTOR and PI3-kinase
inhibitors [25,43].
In addition to NOTCH, a second target we considered was
TLX1 itself. Growth of the TLX1 cell line 9490 was modestly
inhibited by suppression of TLX1 with doxycycline. Our results
confirm similar studies by Riz et al. [33] using shRNA against
TLX1 and by De Keersmaecker et al. [44] using siRNA against
TLX1. Knockdown of TLX1 in ALL-SIL cells in both studies
modestly inhibited cell growth. Despite TLX1 knockdown, both
9490 and ALL-SIL continued to grow. In these studies, we cannot
rule out that a residual level of TLX1 activity after knockdown
prevented a more profound growth inhibition. We followed up our
initial studies by injecting 9490 and primary murine T-ALL cells
into recipient mice. Similar to GSI, administration of doxycycline
had a modest, transient effect on progression and penetrance of T-
ALL. Our data suggests that TLX1 inhibitors may contribute to
T-ALL therapy, but will likely need to be combined with other
agents. Our results suggest that NOTCH inhibitors may be one
possibility. The combination of TLX1 and NOTCH blockade
cooperatively inhibited cell cycle progression in 9490 cells.
The reason for tumor growth despite TLX1 suppression is
unclear. We have shown that administration of doxycycline
effectively suppressed expression of TLX1 and its target gene Ccr7.
Therefore the mechanism of resistance does not appear to be
failure of doxycycline to suppress TLX1 expression or activity. T-
ALL cells may have switched to alternative pathways that
compensate for loss of TLX1. Part of the oncogenic function of
TLX1 may be related to its ability to inhibit T-cell differentiation.
In a recent study, TLX1 was retrovirally expressed in fetal thymic
organ cultures [45]. TLX1 inhibited T-cell differentiation between
the double-negative (DN) and double-positive (DP) thymocyte
stages. Prior to development of T-ALL in our TLX1 mice, we also
identified a partial block in T-cell differentiation. This block was
predominantly between the DP and single-positive (SP) stages
(data not shown), which may explain why the tumors are arrested
at the DP stage. It is possible that secondary genetic lesions are
acquired during leukemogenesis that collaboratively inhibit
differentiation and eventually supplant TLX1. Indeed, doxycy-
cline treatment of 9490 cells fails to release the DP differentiation
arrest (data not shown). A recent study by De Keersmaecker et al.
[44] showed that TLX1 destabilizes the mitotic checkpoint.
TLX1-expressing cells failed to arrest in M phase upon treatment
with agents that disrupt the mitotic spindle. This defect may lead
to aneuploidy resulting in gain of oncogenes and loss of tumor
suppressors. These data raise the possibility that TLX1 drives T-
ALL by inducing secondary leukemogenic modifications. In an
established T-ALL, inhibition of this function of TLX1 would
presumably not affect leukemia survival.
After treatment with doxycycline, we saw the strongest effects in
down-regulation of CCR7 and reduction of lymph node size. We
verified Ccr7 as a target gene of TLX1 in T-ALL, which confirms a
previous study [33]. CCR7 is essential for T-cell homing to lymph
nodes and Peyer’s patches through high endothelial venules [46].
Thus, it is tempting to speculate that the reduction in lymph node
size after doxycycline administration is a result of CCR7 down-
regulation. Furthermore, premature expression of CCR7 in
transgenic mice produces a defect in thymopoiesis [47]. Premature
expression of CCR7 directs DP thymocytes into the medulla and
impedes differentiation into SP cells. It is tempting to speculate
that CCR7 dysregulation may partly explain the T-cell differen-
tiation and lymph node phenotypes induced by TLX1. However,
it is unlikely that CCR7 is the main effector of TLX1-induced
oncogenesis. CCR7 transgenic mice have not been reported to
develop T-ALL [47]. It is likely that there are additional
downstream effectors of TLX1 oncogenic function besides CCR7.
Given the weak dependence of TLX1-initiated leukemia on
TLX1, we agree that defining the downstream targets regulated by
plots are shown in (A) and the scatter plot is shown in (B). Horizontal lines indicate average percent circulating DP cells in each cohort. (C) Kaplan-
Meier curve showing fraction of recipient mice treated with DMSO (Placebo) or GSI developing T-ALL over time. (D) Western blot showing the
expression of activated (cleaved) NOTCH1 in the DMSO or GSI-treated tumors. FvB = normal FvB/N thymus, negative control. DMSO or GSI was
injected 16 hours prior to analysis. These experiments were repeated twice with similar results.
doi:10.1371/journal.pone.0016761.g004
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PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16761TLX1 may serve more academic than practical purpose. Since
inhibiting TLX1 has only modest effects, drugs or agents that
inhibit its downstream targets will likely have modest or even
weaker effects on leukemia growth. Single agent therapy that
inhibits TLX1 or its downstream genes would be predicted to have
weak effects in T-ALL patients. At first, TLX1 appeared to be an
attractive therapeutic target. The TLX1-regulated gene set is
dispensable for a healthy life [8]. However, upon further study, the
TLX1-regulated gene set also appears to be dispensable for a
healthy tumor. The biological pathways impacted by TLX1 have
lost their importance in the established tumor. They have been
supplanted by stronger, unknown oncogenic pathways. Our results
suggest that the NOTCH pathway may be one of these pathways.
However, given the weak dependence of these tumors on
NOTCH signaling, there seem to be signaling pathways that are
more essential than NOTCH. Identifying and characterizing these
essential pathways and downstream gene sets is a clear future
direction of this mouse model. In our opinion, pursuing these
pathways will be a more fruitful endeavor than pursuing TLX1 or
NOTCH gene sets in TLX1-type T-ALL.
Our mouse model is similar to another TLX1-T-ALL mouse
model described in the recent De Keersmaecker study [44]. In our
mouse model, the TLX1 transgene is regulated by TTA, which is
in turn regulated by the proximal Lck promoter. In the De
Keersmaecker mouse model, the TLX1 transgene is regulated
directly by the proximal Lck promoter. In both mouse models, T-
ALL is induced with similar median latencies (25 or 35 weeks in
our model and 27, 32, or 46 weeks in the Keersmaecker model).
T-ALL was induced with a lower penetrance in our mouse model
(overall ,40%) compared to the De Keersmaecker model (overall
,90%). The rate of secondary Notch1 mutations was higher in
our mouse model (,67%) compared to the De Keersmaecker
mouse model (,12%). The reason for the differences in
penetrance and NOTCH mutation rate is unclear, but may be
related to strain differences and/or TLX1 expression. Given the
requirement to generate sufficient levels of TTA to transactivate
the TLX1 transgene, our mouse model would be expected to
induce TLX1 expression at a later developmental stage when
compared to the De Keersmaecker mouse model. Both mouse
models show that TLX1 can induce T-ALL. The De Keers-
maecker study goes further to suggest mechanisms by which
TLX1 induces T-ALL from normal T-cells. The TLX1 gene set
may induce aneuploidy and differentiation arrest. Our study goes
further to suggest that established TLX1 tumors have activated
strong pathways that render the TLX1 gene set largely dispensable
in the established tumor.
Development of T-ALL is a multistep acquisition of transfor-
mative genetic lesions that accumulate over time. Identifying and
understanding these genetic lesions are critical steps to determine
whether these lesions are worthwhile targets for clinical investiga-
tion. Our mouse studies evaluate the potential of NOTCH and
TLX1 as therapeutic targets in TLX1 T-ALL. Targeting these
oncogenes only has weak, transient effects. However, we cannot
rule out that NOTCH or TLX1 inhibitors may participate in
combination therapy with other targeted agents. Clearly, activa-
tion of unknown, important oncogenic pathways compensate for
loss of NOTCH signaling and TLX1. Given the excellent track
record of T–ALL mouse models, we hope that our mouse model
will launch a new investigation to implicate these pathways and
evaluate molecularly targeted therapy in TLX1-driven leukemia.
Materials and Methods
Ethics statement
Experiments were performed according to guidelines from the
National Institutes of Health with approved protocols from the
Institutional Animal Care and Use Committees at the University
of Pennsylvania (Permit #466100) and the University of Michigan
(Permit #10298). Mice that developed T-ALL may have
experienced discomfort. Signs included increased abdominal girth
from hepatosplenomegaly and/or bleeding from thrombocytope-
nia, lethargy from anemia, tachypnea (noted by a hunched
posture) from thymic lymphoma, dehydration, decreased activity,
diminished grooming, and cachexia. Mice with T-ALL were
susceptible to infection. Mice were observed daily by laboratory
staff and animal technicians and weighed twice a week to detect
weight loss. The breeding colonies were monitored twice weekly
by laboratory staff and animal technicians. If the mice decom-
pensated, they were immediately euthanized by CO2 and
secondarily with pneumothorax induction with a scalpel to
ameliorate suffering.
Mice
LTH1 mice were a gift from Diane Mathis (Harvard). These
mice, originally on the C57BL/6 background, were backcrossed at
least seven generations to the FvB/N background. These
backcrossed mice were called ‘‘L’’ mice. To make ‘‘H’’ mice, the
TMILA8PS backbone was removed from the HOX11-TMILA
plasmid by digestion with NotI. The remaining DNA fragment
was microinjected into C57BL/6J x SJL/J F1 embryos by the
University of Pennsylvania Transgenic and Chimeric Mouse
Facility (Jean Richa). The resulting H mice were backcrossed at
least six generations to the FvB/N background. All mice were
housed in specific pathogen-free facilities at the University of
Pennsylvania and the University of Michigan. Experiments were
performed according to guidelines from the National Institutes of
Health with approved protocols from the Institutional Animal
Care and Use Committees at the University of Pennsylvania
(Permit #466100) and the University of Michigan (Permit
#10298).
Constructs and retroviruses
The TetO expression vector TMILA8PS was obtained from
Lewis Chodosh (University of Pennsylvania). The human TLX1
Figure 5. The TLX1 T-ALL cell line 9490 is sensitive to TLX1 withdrawal. (A) 9490 cells were treated with or without doxycycline for 12 days.
Extrapolated cell number is shown over time. Average cell numbers of biological triplicates are shown. (B) At 48 hours after addition of doxycycline,
TLX1 expression was measured by Western blot using the antibody 1D7. ALL-SIL is shown as a positive control. b-actin expression is shown as a
loading control. (C) At 48 hours after addition of doxycycline, expression of TLX1 and putative TLX1 targets RUNX1, ALDH1A, HMGA2, CCR7, and
SLC2A3 were measured by qPCR. Average expression values of experimental triplicates are shown relative to 18s and normalized to untreated 9490
cells. FvB = wildtype FvB/N thymus. (D) 9490 cells were retrovirally transduced with the NGFR control vector or human TLX1 in the NGFR vector,
treated with vehicle or doxycycline for 48 hours, and then measured for CCR7 and SLC2A3 expression by qPCR. Average expression values of
experimental triplicates are shown relative to 18s and normalized to NGFR-transduced controls. (E) 9490 cells transduced with NGFR or TLX1 were
injected into lethally irradiated recipients. These mice were then treated with placebo or doxycycline. Kaplan-Meier curves showing development of
T-ALL over time. At 4 weeks after transplant, cervical lymph node (F) and spleen (G) weights were measured. Average weights of each cohort are
shown by horizontal lines. These experiments were repeated twice with similar results.
doi:10.1371/journal.pone.0016761.g005
NOTCH and TLX1 Inhibition in T-ALL
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16761Figure 6. Primary TLX1 T-ALLs are sensitive to TLX1 withdrawal in vivo. TLX1 T-ALLs from LH mice were injected into lethally irradiated FvB
recipients. Mice were treated with either placebo or doxycycline. Control mice were injected with rescue bone marrow cells alone. At 4 weeks after
transplant, the percent circulating CD4
+CD8
+ (DP) cells was measured. Representative dot plots are shown in (A) and the scatter plot is shown in (B).
Horizontal lines indicate average percent circulating DP cells in each cohort. (C) At 3 weeks after transplant, the cervical lymph node weight (C) and
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NotI site in the human TLX1 cDNA was ablated by a G to T point
mutation of base pair #189 (relative to the translational start site)
using the QuikChange XL Site-Directed Mutagenesis Kit
(Stratagene). This mutation is silent. The mutated TLX1 cDNA
was then subcloned into the TMILA8PS vector at the HindIII and
SpeI sites to generate the construct HOX11-TMILA. The NGFR-
expressing MSCV-IRES-NGFR construct was obtained from
Warren Pear (University of Pennsylvania). To make the HOX11-
NGFR construct, the human TLX1 cDNA was subcloned into the
Bgl2 and EcoR1 sites of MSCV-IRES-NGFR. High titer
retroviral supernatant was produced using transient transfection
of 293T-cells and assessed for GFP titer by plating on 3T3
fibroblasts.
Bone marrow transplantation
Frozen TLX1 T-ALL cells were thawed, washed with PBS,
and then injected into lethally irradiated (900 rads) FvB/N
recipients at 1 million cells per mouse. 200,000 competitor FvB/
N normal bone marrow cells were injected for hematopoietic
support. Mice were maintained on antibiotics in drinking water
for 2 weeks after BMT. Mice were bled every 2–3 weeks to
monitor blood counts and evaluate the presence of circulating
immature T-cell progenitors by flow cytometry. For TLX1
inhibition experiments, the mice were fed placebo water (5%
sucrose) or doxycycline water (Research Products International,
2 g/L in 5% sucrose) starting two days prior to transplantation.
For NOTCH inhibition experiments, the mice were intraperi-
toneally injected with c-secretase inhibitors (DBZ, EMD
Chemicals) at 3 weeks after transplantation as previously
described [25,48].
Flow cytometry
Flow cytometry antibodies from BD, eBioscience, or Biolegend
were as follows: CD4 (RM4-5), CD8 (53-6.7), CD24 (M1/69),
CD127 (SB/199), Thy1.1 (HIS51), Cells were stained on ice in
PBS containing 2% fetal bovine serum, 10 mM Hepes and 0.02%
NaN3 after blocking with rat and mouse IgG (Sigma, St. Louis,
MO) and 24G2 cell supernatant. Acquisition was performed on a
FACS-Calibur (Becton-Dickinson) or C6 (Accuri). Annexin V
staining was performed by staining with APC Annexin V antibody
according to manufacturer’s protocol (Becton-Dickinson). Flow
sorting was performed on a FACS-Diva. Dead cells and doublets
were excluded based on FSC and SSC characteristics. Data were
analyzed with FlowJo (Tree Star, San Carlos, CA).
Cell cultures
Primary tumor cells extracted from leukemic mice were grown
in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine
serum (Hyclone), 2 mM L-glutamine, 2-mercaptoethanol
(0.0005% (v/v), Sigma, St. Louis, MO), and antibiotics. 293T-
cells were maintained in Dulbecco’s modified Eagle medium
(DMEM) (Invitrogen) with the same supplements except 2-
mercaptoethanol. Cells were grown at 37uC under 5% CO2.
Treatment of cell lines with GSI (JC19 or DBZ) was performed as
described [49]. JC-19 was obtained from Yueming Li.
Quantitative real time PCR (qPCR)
Total RNA was prepared using Trizol (Invitrogen). Random-
primed total RNAs (2 mg) were reverse-transcribed with Super-
Script II (Invitrogen). Expression were validated using primer/
probe sets from TaqManH Gene Expression Assays (Applied
Biosystems). Mouse Deltex1, Hes1, c-Myc, Nrap, and Cd25, primer
sets have been previously described [49]. Sequence of 18s primer
set has been described [50]. The sequence of the Runx1 primer set
is as follows: Forward, GCAGGCAACGATGAAAACTACT;
Reverse, GCAACTTGTGGCGGATTTGTA. The sequence of
the TLX1 primer set (659–777) is as follows: Forward, TCC-
ACCGCCAGAAGTACC; Reverse CTGCCGTCTCCACTTT-
GTC. The sequence of the Aldha1 primer set is as follows:
Forward, CCGACTTGGACATTGCTGT; Reverse, AGCTCG-
CTCAACACTCCTTT. The sequence of the Hmga2 primer set is
as follows: CTTGTCCCTCTGCATCTGTG; Reverse, AAACC-
GAGGAGAGAGTGGAA. The sequence of the Ccr7 primer set is
as follows: Forward, GAGGGCTAGCTGGAGAGAGA; Re-
verse, GCAGAAGCACACCTGGAAA. The sequence of the
Slc2a3 primer set is as follows: Forward, GTCACAGGAGAAG-
CAGGTGA; Reverse, AGAACACAGCATTGATCCCA. Tran-
scripts were amplified with either TaqMan Universal PCR Master
Mix or Sybr Green PCR Master Mix (Applied Biosystems) on the
ABI Prism 7500 sequence detection system (Applied Biosystems).
Statistical analysis
Comparison of survival curves was performed using a log rank
(chi-square) analysis provided through the Prism 4.03 software
package (GraphPad Software). Student’s t-test analysis was
provided through Prism. A p-value of less than 0.05 was
considered to be significant.
Western blotting
Whole cell extracts prepared from the lymphomas of recipient
mice were immunoprecipitated with the anti-TLX1 antibody
(1D7, Santa Cruz). Immunopreciptates were analyzed for TLX1
expression by western blotting with the 1D7 antibody. Cleaved
NOTCH1 was detected in whole cell extracts using the antibody
recognizing the V1744 epitope (Cell Signaling Technology). b-
actin was detected in whole cell extracts using the AC-74 antibody
(Sigma).
DNA sequencing
High molecular weight DNA was isolated from fresh or snap-
frozen thymic lymphomas. Sequencing for murine HD and PEST
mutations in primary mouse tumors samples was performed as
described [51].
Supporting Information
Figure S1 Gross pathology of TLX1-initiated T-ALL. T-
ALL infiltrates the thymus and lymph nodes T-ALL induced by
TLX1 (LH) or age matched L transgenic mouse control (L).
5.0 mm marker is inserted for size comparison. Mesenteric lymph
nodes are shown.
(TIF)
spleen weight (D) were measured. Average weights of each cohort are shown by horizontal lines. (E) Kaplan-Meier curve showing fraction of recipient
mice developing T-ALL over time. (F) Expression of TLX1 and the TLX1 target gene CCR7 were measured by qPCR in placebo-treated or doxycycline-
treated T-ALLs. Average expression values of biological replicates are shown relative to 18s and normalized to placebo-treated controls. These
experiments were repeated twice with similar results.
doi:10.1371/journal.pone.0016761.g006
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ALL infiltrates the thymus and lymph nodes of T-ALL induced by
TLX1 (LH) or age matched L transgenic mouse control (L). 50X
magnification. Hematoxylin-Eosin stain.
(TIF)
Figure S3 Effect of NOTCH inhibition on IL-7Ra
expression. A. 9490 cells were treated with DMSO or GSI
(JC-19) for 60 hours and then analyzed for IL-7Ra (CD127)
expression by flow cytometry. B. Mean fluorescence intensity
(MFI) of IL-7Ra expression as measured by flow cytometry.
Average intensities of biological triplicates are shown. Experiments
were repeated twice with similar results.
(TIF)
Figure S4 Effect of concurrent TLX1 and NOTCH
inhibition on apoptosis. A. 9490 cells were treated with
DMSO, GSI (JC-19), doxycycline (DOX), or GSI + DOX for
60 hours and then analyzed for % apoptotic cells by PI assay. Cells
were pre-treated with doxycycline for 24 hours in addition.
Representative histograms are shown. B. Column graph showing
average % apoptotic cells of biological triplicates. Experiments
were repeated twice with similar results.
(TIF)
Figure S5 Effect of concurrent TLX1 and NOTCH
inhibition on cell cycle progression. A. 9490 cells were
treated with DMSO, GSI (JC-19), doxycycline (DOX), or GSI +
DOX for 60 hours. Cell cycle analysis of non-apoptotic cells was
performed by PI assay. Cells were pre-treated with doxycycline for
24 hours in addition. Representative histograms are shown. B.
Column graph showing average % total live gated cells in G1, S,
and G2/M phases of the cell cycle of biological triplicates.
Experiments were repeated twice with similar results.
(TIF)
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